Your browser doesn't support javascript.
loading
Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor.
Harada, Hideyuki; Shikama, Naoto; Notsu, Akifumi; Shirato, Hiroki; Yamada, Kazunari; Uezono, Haruka; Koide, Yutaro; Kubota, Hikaru; Yamazaki, Takuya; Ito, Kei; Heianna, Joichi; Okada, Yukinori; Tonari, Ayako; Katoh, Norio; Wada, Hitoshi; Ejima, Yasuo; Yoshida, Kayo; Kosugi, Takashi; Takahashi, Shigeo; Komiyama, Takafumi; Uchida, Nobue; Miwa, Misako; Watanabe, Miho; Nagakura, Hisayasu; Ikeda, Hiroko; Saito, Tetsuo; Asakawa, Isao; Takahashi, Takeo; Shigematsu, Naoyuki.
Afiliación
  • Harada H; Division of Radiation Therapy, Radiation and Proton Therapy Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Shikama N; Department of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
  • Notsu A; Clinical Research Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Shirato H; Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo-shi, Hokkaido, 060-8638, Japan.
  • Yamada K; Department of Radiation Oncology, Seirei Mikatahara General Hospital, 3453 Mikatahara, Chuo-ku, Hamamatsu-shi, Shizuoka, 433-8558, Japan.
  • Uezono H; Department of Radiation Oncology, Hyogo Cancer Center, 13-70, Kitaojicho Akashi-shi, Hyogo, 673-0021, Japan.
  • Koide Y; Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya-shi, Aichi, 464-8681, Japan.
  • Kubota H; Division of Radiation Oncology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe-shi, Hyogo, 650-0017, Japan.
  • Yamazaki T; Department of Radiology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki, 852-8501, Japan.
  • Ito K; Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
  • Heianna J; Department of Radiation Oncology, Nanbu Tokushukai Hospital, 171-1 Hokama, Yaese-cho, Shimajiri-gun, Okinawa, 901-0493, Japan.
  • Okada Y; Department of Radiation Oncology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan.
  • Tonari A; Department of Radiation Oncology, Kyorin University Hospital, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan.
  • Katoh N; Department of Radiation Oncology, Hokkaido University Faculty of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo-shi, Hokkaido, 060-8638, Japan.
  • Wada H; Department of Radiation Oncology, Southern TOHOKU Proton Therapy Center, 7-172 Yatsuyamada, Koriyama-shi, Fukushima, 963-8052, Japan.
  • Ejima Y; Department of Radiology, Dokkyo Medical University, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi, 321-0293, Japan.
  • Yoshida K; Department of Radiology, Keio University School of Medicine, 5 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
  • Kosugi T; Department of Radiation Oncology, Fujieda Municipal General Hospital, 4-1-11 Surugadai, Fujieda-shi, Shizuoka, 426-8677, Japan.
  • Takahashi S; Department of Radiation Oncology, Kagawa University Hospital, 1750-1 Ikenobe, Miki, Kita-gun, Kagawa, 761-0793, Japan.
  • Komiyama T; Department of Radiology, University of Yamanashi, 1110 Shimokato, Chuo-shi, Yamanashi, 409-3898, Japan.
  • Uchida N; Department of Radiation Oncology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo, 108-0073, Japan.
  • Miwa M; Department of Radiology, Sendai Kousei Hospital, 1-20 sutsumidori, Amemiya, Aoba-ku, Sendai-shi, Miyagi, 981-0914, Japan.
  • Watanabe M; Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8670, Japan.
  • Nagakura H; Department of Radiology, KKR Sapporo Medical Center, Hiragishi Ichijo 6-3-40, Toyohira-ku, Sapporo-shi, Hokkaido, 062-0931, Japan.
  • Ikeda H; Department of Radiation Oncology, Osaka City General Hospital, 2 Chome-13-22 Miyakojimahondori, Miyakojima-ku, Osaka-shi, Osaka, 534-0021, Japan.
  • Saito T; Department of Radiation Oncology, Ariake Medical Center, 2600, Arao, Arao-shi, Kumamoto, 864-0041, Japan.
  • Asakawa I; Department of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara, 634-8522, Japan.
  • Takahashi T; Department of Radiation Oncology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe-shi, Saitama, 350-8550, Japan.
  • Shigematsu N; Department of Radiology, Keio University School of Medicine, 5 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
J Radiat Res ; 2024 Aug 20.
Article en En | MEDLINE | ID: mdl-39162649
ABSTRACT
Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/ß = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20-30 Gy (24%), 30-40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4-5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1-9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2-76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Radiat Res Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Radiat Res Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido